Journavx (Suzetrigine): Non-Opioid Pain Treatment Appoved by FDA
March 07, 2025 – On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (Suzetrigine), 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx (Suzetrigine) reduces pain by targeting a …
Journavx (Suzetrigine): Non-Opioid Pain Treatment Appoved by FDA Read more »